Orchid Pharma Limited (ORCHPHARMA)

Healthcare · Pharmaceuticals & Biotechnology · NSE · Updated 15 July 2026

₹1,101.4 ↑ 48.85% (1Y)

🎯 Key Takeaways

Orchid Pharma is in a strategic rebuild phase following the Dhanuka Laboratories merger, transitioning from near-term margin pressures to long-term growth through U.S.
Revenue declined 2.4% QoQ to ₹217 in Q3FY25.
⚠️ 1) Execution risk around timely Cefiderocol launch in Q2-Q3 2027 amid regulatory and commercialization complexities in the U.S. market. 2) Margin pres

Market Cap

₹3,614

P/E Ratio

32.3

Div Yield

0.00%

Promoter

0.0%

✨ Ask AI About ORCHPHARMA 📊 Interactive Charts

📖 The Story

Orchid Pharma is in a strategic rebuild phase following the Dhanuka Laboratories merger, transitioning from near-term margin pressures to long-term growth through U.S. market expansion and key product launches like Cefiderocol and 7ACA. The company is leveraging its expanded scale and FDA-approved facilities to target a $1.2 billion U.S. segment, with management targeting 10-15% revenue growth in FY27 and maintaining 12% EBITDA margins for its base business.

📰 What's Happening

The company completed the NCLT-approved merger with Dhanuka Laboratories in June 2026, creating a combined entity with Rs.1400-1500 crore turnover and Rs.200-250 crore EBITDA. Management highlighted strategic progress including commissioning of the 7ACA project in Q1 2027, updated Cefiderocol launch window to Q2-Q3 2027, and five planned U.S. product launches. Capex of INR50 crores has been allocated for fill-finish facilities tied to Cefiderocol, while gross margins are recovering to 31-32% by Q4 after Q1 inventory losses from 15-20% price drops. The merger has enabled operational consolidation and elimination of inter-company transactions.

Source: Stock Announcements

📊 Quarterly Results (₹ Cr)

Metric	Q4FY23	Q1FY24	Q2FY24	Q3FY24	Q4FY24	Q1FY25	Q2FY25	Q3FY25
Revenue	210	183	199	221	217	244	223	217
Operating Profit	81	24	32	43	42	40	38	35
OPM %	18.9%	12.1%	11.7%	16.0%	13.3%	13.3%	13.6%	12.1%
Net Profit	59	9	20	29	33	29	27	21
EPS	₹14.49	₹1.85	₹4.30	₹6.18	₹6.81	₹5.79	₹5.37	₹4.10

Revenue declined 12% YoY to ₹811 crores in FY26, with EBITDA down 35% to ₹101 crores, reflecting near-term headwinds from pricing pressures and inventory adjustments. However, quarterly trends show stabilization, with Q4 FY26 revenue at ₹238 crores and EBITDA at ₹42.3 crores, indicating sequential improvement. The company attributes margin recovery to gross margin expansion to 31-32% by Q4, supported by stable 7ACA pricing at $61 (range: $55-$65) and operational efficiencies post-merger. The financial trajectory reflects a deliberate shift from high-margin legacy performance toward sustainable growth in higher-value segments.

🔮 Management Outlook & What's Next

Management maintains a 12% EBITDA margin guidance for the base business and targets 10-15% revenue growth in FY27, underpinned by U.S. market expansion and five planned product launches. Key forward-looking statements include the Cefiderocol launch in Q2-Q3 2027, lifetime sales projection of $1-2 billion for Enmetazobactam, and commissioning of the Shionogi plant in December 2026 enabling H2 2027 Indian launch. Capex of INR50 crores is specifically tied to fill-finish facilities for Cefiderocol, with 7ACA pricing remaining stable in the $55-$65 range.

Extracted from official company announcements. Not StockFin.ai's opinion.

⚖️ Peer Comparison — Pharmaceuticals & Biotechnology

Company	MCap (₹ Cr)	P/E	ROCE	ROE	D/E
Sun Pharmaceutical Industries Limited	4.51 L Cr	41.3	20.3%	15.1%	0.03
Divi's Laboratories Limited	1.79 L Cr	72.4	22.1%	16.6%	0.00
Torrent Pharmaceuticals Limited	1.49 L Cr	80.1	—	—	—
Cipla Limited	1.16 L Cr	25.4	19.4%	14.6%	0.00
Dr. Reddy's Laboratories Limited	1.12 L Cr	20.0	19.7%	16.6%	0.12
Lupin Limited	1.04 L Cr	36.2	—	—	—
Mankind Pharma Limited	1.03 L Cr	49.2	—	—	—
Zydus Lifesciences Limited	1.02 L Cr	22.5	—	—	—
Aurobindo Pharma Limited	87,806	25.3	—	—	—
Laurus Labs Limited	71,455	356.8	—	—	—

🔗 Peer Stock Analyses

SUNPHARMA DIVISLAB TORNTPHARM CIPLA DRREDDY

⚠️ Risk Factors

1) Execution risk around timely Cefiderocol launch in Q2-Q3 2027 amid regulatory and commercialization complexities in the U.S. market. 2) Margin pressure from pricing adjustments and inventory corrections, with gross margins recovering only gradually to 31-32% by Q4. 3) Integration risks from the Dhanuka Laboratories merger, including realization of synergies and operational harmonization. 4) Dependence on a small number of high-value products for long-term growth, with Enmetazobactam's $1-2 billion lifetime sales projection contingent on market adoption.

📋 Recent Filings

🧠 Analyst's Read

Orchid Pharma is transitioning from a period of financial contraction to a growth phase anchored in strategic U.S. expansion and product launches, but near-term results reflect deliberate margin management and integration challenges. Investors should monitor the Cefiderocol launch timeline, pace of U.S. product adoption, and margin trajectory as key inflection points in the company's turnaround narrative.

Based on filing content and financial data. Not a recommendation.

Read the full analysis

Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.

2 free AI queries per day.

✨ Deep Dive with AI on ORCHPHARMA

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-07-15.

📡 Get AI alerts when ORCHPHARMA files new disclosures

Track ORCHPHARMA filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track ORCHPHARMA — Free

Free account · 2 AI queries/day